Welcome to Dividends Inside
Welcome to Dividends Inside!

The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.

Syros Pharmaceuticals Inc.

SYRS
$0.00 (+ $0.00 + 0.00%)
Last updated: 2026-05-20 17:18 UTC
SYRS Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS87184Q1076
Market Price0.0
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPSN/A
Market Cap$21,465
Book Value-0.41
Price to Book-0.002
Beta1.0
52w High0.3
52w Low0.0
Next Earnings DateN/A
About the Company
Syros Pharmaceuticals Inc. is a biopharmaceutical company that focuses on discovering and developing medicines to control the expression of genes with the goal of treating diseases. The primary function of Syros Pharmaceuticals is to leverage its proprietary platform to identify and target gene regulatory regions to create therapeutics for cancer and other challenging diseases. Key features of the company include its emphasis on precision medicine, using gene regulatory analysis to pioneer drug discovery and development. Syros Pharmaceuticals plays a crucial role in the biotechnology sector by expanding treatment options for conditions that are currently underserved by existing therapies. Its innovative approach is redefining how genetic medicine can be applied to modern healthcare problems. Based in Cambridge, Massachusetts, Syros aims to produce novel therapeutics that address the underlying causes of disease, offering hope for patients through its groundbreaking scientific research and development.
Price History
Latest News for SYRS
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital
CHICAGO, July 16, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital. Founded to address urgent unmet needs in rare and life-threatening diseases, Quetzal brings together a team of seasoned executives, scientific pioneers, and biotech & pharmaceutical veterans committed to delivering transformative therapies to patients around the world. At the core of Quetzal’s mission is a belief tha